drugset
Drugs / ADRIFORANT
last change Aug 2020 re-read 9 days ago

ADRIFORANT

also known as PF-03893787 · ZPL-3893787 · ZPL389 · NVP-ZPL389-NX · PF-3893787 · ZPL-389-NX

Small molecule targets HRH4 via inhibition

Developed for
atopic eczema · asthma · psoriasis
Investigated by
Novartis Pharmaceuticals · Pfizer · Ziarco Pharma Ltd

Trials 6

today NCT03948334 · Ph 2 NCT03517566 · Ph 2 NCT02618616 · Ph 2 NCT02424253 · Ph 2 NCT00992342 · Ph 1 NCT00856687 · Ph 1
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00992342 Nov 2009 → Mar 2010 — Pfizer Completed No outcome recorded
Phase 1 NCT00856687 Apr → Dec 2009 asthma Pfizer Completed No outcome recorded
Phase 24 trials · 2 missed
Phase 2 NCT03948334 Apr 2019 → Jul 2020 atopic eczema Novartis Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT03517566 Nov 2018 → Jul 2020 atopic eczema Novartis Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT02618616 Jan → Dec 2016 psoriasis Ziarco Pharma Ltd Completed Missed primary
Phase 2 NCT02424253 May 2015 → Jan 2016 atopic eczema Ziarco Pharma Ltd Completed Missed primary

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as ADRIFORANT ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗
Known as NVP-ZPL389-NX ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗
Known as PF-03893787 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00856687 ↗
1

NCT00992342 ↗
Known as PF-3893787 ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗
Known as ZPL-389-NX ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗
Known as ZPL-3893787 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02618616 ↗
1

NCT02424253 ↗
Known as ZPL389 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03517566 ↗
1

NCT03948334 ↗
Action Inhibit “Histamine H4 receptor antagonist” CHEMBL1915540 ↗
Modality Small molecule — CHEMBL1915540 ↗
Route Oral “Oral, two doses 12 hours apart” NCT00856687 ↗
Target HRH4 “Histamine H4 receptor antagonist” CHEMBL1915540 ↗